

REMARKS

In the Office Action, the Examiner set forth ten groups of claims alleging that each invention or group of inventions are distinct inventions. The groups set forth by the Examiner are noted below:

Group I, the instances wherein R^1 is a 1,2,3-triazolo[4,5-b]pyridine, R^3 represents non-heterocyclic groups, R^4 and R^5 form an imidazo[2,1-b]-1,3,4-thiadiazole, classified in class 546, subclass 117.

Group II, the instances wherein R^1 is a benzotriazole, R^3 represents non-heterocyclic groups, R^4 and R^5 form an imidazo[1,2-a]imidazole classified in class 546, subclass 273.1.

Group III, the instances wherein R^1 is a quinazoline, R^3 represents non-heterocyclic groups, R^4 and R^5 form an imidazo[1,2-a]pyridine classified in class 544, subclass 283.

Group IV, the instances wherein R^1 is a quinazoline, R^3 represents non-heterocyclic groups, R^4 and R^5 form an imidazo[1,2-a]pyrimidine classified in class 544, subclass 284.

Group V, the instances wherein R^1 is a quinazoline, R^3 represents non-heterocyclic groups, R^4 and R^5 form an imidazo[2,1-b]-1,3,4-thiadiazole, classified in class 544, subclass 245.

Group VI, the instances wherein R^1 is a benzoxazole, R^3 represents non-heterocyclic groups, R^4 and R^5 form an imidazo[1,2-a]pyridine, classified in class 546, subclass 113.

Group VII, the instances wherein R^1 is a benzoxazole, R^3 represents non-heterocyclic groups, R^4 and R^5 form a 1,3,4-thiadiazole, classified in class 546, subclass 114.

Group VIII, the instances wherein R¹ is a benzoxazole, R³ represents non-heterocyclic groups, R⁴ and R⁵ form an imidazo[1,2-a]pyrimidine, classified in class 544, subclass 253.

Group IX, any instances not included in the above groups since claim 1 is too vague to further group.

Group X, Claim 15, drawn to multiple uses, classified in class 514, various subclasses.

The Examiner alleges that the claims listed in each of the groups claim distinct inventions because they have separate uses, are mutually exclusive and independent inventions. Applicants suggest and elect an alternative group (Group XI) as follows:

Group XI, the instances wherein R¹ is a quinoline, R³ represents a (C₁-C₆) alkyl or (C₃-C₁₀) cycloalkyl group, R⁴ and R⁶ taken together with the imidazol ring to which they are attached form a core fused imidazopyridinyl, imidazopyrimidinyl, imidazopyrazinyl, imidazothiazolyl or imidazothiadiazolyl group.

If the Examiner accepts this grouping, Applicants elect the compound 6[2-(6-methyl-pyridin-2-yl)-imidazol[1,2-a]pyrimidin-3-yl]-quinoline as the species to first be examined. Antecedent basis for this compound is found at Example 5 of the application as filed. Claims 1, 4, 9, 12, and 13 have been amended to delete non-elected subject matter. Claim 15 has been withdrawn. Applicants reserve the right to prosecute the non-elected subject matter in subsequent applications.

Appl. No. 10/783,251
Amendment dated October 20, 2006
Reply to Office Action of September 22, 2006


Applicants invite the Examiner to call the undersigned if a telephone interview would advance the prosecution.

Finally, the undersigned notes that subsequent correspondence should be addressed to:

Rosanne Goodman
Pfizer Inc.
Patent Department
2800 Plymouth Road
Ann Arbor, MI 48105
Tel. (734) 622-4182

Respectfully submitted,

Dated: October 20, 2006


Rosanne Goodman
Registration No. 32,534
Pfizer Inc.
2800 Plymouth Road
Ann Arbor, MI 48105
Telephone: (734) 622-4182
Facsimile: (734) 622-1553